Mapi Pharma Ltd.
Value-added oral and depot dosage drugs
This article was originally published in Start Up
Mapi Pharma Ltd. intends to create added-value and patentable products based on combining off-patent drugs with its innovative oral and depot delivery systems, both for its in-house pipeline and for its clients. The Israeli start-up also manufactures complex, bulk, active pharmaceutical ingredients, generic and innovative intermediates, and finished dosage forms.